These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
731 related articles for article (PubMed ID: 33977343)
1. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome. Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343 [TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody. Urai S; Watanabe M; Bando H; Motomura Y; Yamamoto M; Tachihara M; Kanzawa M; Fukuoka H; Iguchi G; Ogawa W Front Immunol; 2023; 14():1284301. PubMed ID: 38035072 [TBL] [Abstract][Full Text] [Related]
3. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Di Dalmazi G; Ippolito S; Lupi I; Caturegli P Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671 [No Abstract] [Full Text] [Related]
4. Thyroid disorders induced by checkpoint inhibitors. Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549 [TBL] [Abstract][Full Text] [Related]
5. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029 [TBL] [Abstract][Full Text] [Related]
6. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases]. Gu YC; Liu Y; Xie C; Cao BS Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206 [TBL] [Abstract][Full Text] [Related]
7. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases. Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523 [TBL] [Abstract][Full Text] [Related]
8. Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis. van der Leij S; Suijkerbuijk KPM; van den Broek MFM; Valk GD; Dankbaar JW; van Santen HM Front Endocrinol (Lausanne); 2024; 15():1400841. PubMed ID: 39135626 [TBL] [Abstract][Full Text] [Related]
9. Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis. Yang L; Zhang Y; Chen X; Liu K; Zhou Y; Wang S Clin Endocrinol (Oxf); 2024 Aug; 101(2):130-139. PubMed ID: 38753540 [TBL] [Abstract][Full Text] [Related]
10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224 [TBL] [Abstract][Full Text] [Related]
11. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. Deligiorgi MV; Liapi C; Trafalis DT Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372 [TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review. Fukuda I J Nippon Med Sch; 2023 May; 90(2):149-156. PubMed ID: 36823122 [TBL] [Abstract][Full Text] [Related]
13. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543 [TBL] [Abstract][Full Text] [Related]